Retinal thickness variation in the diabetic patient measured by the retinal thickness analyser

Dov Weinberger, Ruth Axer-Siegel, David Landau, Yuval Yassur

Abstract

Aim—To evaluate the potential of the retinal thickness analyser (RTA) as an objective tool for assessment and follow up of diabetic macular oedema.

Methods—A prototype of the RTA that operates on the principle of laser slit biomicroscopy was used. Retinal thickness was obtained in 41 eyes of 41 diabetic patients. The clinical diagnosis was cystoid macular oedema (CMO) in 10 eyes, clinically significant macular oedema (CSMO) without retinal cysts in 21 eyes, and “dry” macula following grid pattern laser treatment in 10 eyes. The control group consisted of 46 eyes of age matched healthy volunteers.

Results—In normal eyes (46 eyes), the foveal thickness measured was 178 (SD 44) µm and the macular thickness around the fovea was 311 (51) µm. The eyes with CMO displayed the largest foveal thickening, 875 (287) µm (390% increase compared with normal values). The average thickness of the fovea in the non-cystoid CSMO group was 427 (175) µm (144% increase compared with normal fovea). The average thickness of the foveal centre in eyes judged as having “dry” macula after laser treatment was 315 (71) µm (77% increase compared with normal value and a 26% decrease in thickness compared with the CSMO eyes). Statistically significant differences were found in central thickness between these four groups (p = 0.0001). The average thickness at 500 µm surrounding the fovea was 566 (202) µm in the CSMO eyes compared with 311 (51) µm in normal eyes (80% increase). The “dry” macula group (after undergoing laser treatments) had an average thickness of 414 (94) µm (27% decrease compared with CSMO eyes and a 33% increase compared with eyes of healthy controls).

Conclusions—RTA is a system for quantifying macular thickness and imaging of macular pathology. The system can be a useful tool for diagnosis of macular diseases and for evaluation of the effect of treatment modalities.

Retinal thickness analysis is of great importance in understanding pathophysiology and treatment efficacy in many macular diseases, including diseases in which the retina becomes thicker, such as cystoid macular oedema, diabetic macular oedema, or diseases in which the retinal tissue becomes thinner or is missing (macular hole, cystoid macular oedema, and scarred area after laser treatment).

The assessment of retinal thickening or thinning by slit lamp biomicroscopy or stereo fundus photography is often difficult, very subjective, and of questionable reliability. Moreover, these methods necessitate the time consuming involvement of a highly skilled observer.

A quantitative method of measuring retinal thickness and visualisation of fine retinal structures has already been introduced by Zeimer et al,1 Shahidi et al,2 and Mori et al;3 this method is based on angular delivery of a narrow, green, helium neon laser beam onto the retina and detection of the intersection of the slit with the retinal structures.

Recently, an instrument called the retinal thickness analyser (RTA, Talia Technology Ltd, Mevaseret Zion, Israel), based on the same method has been introduced by Zeimer et al.1 The instrument is able to scan and measure the thickness of a selected retinal area in various regions of the fundus, including the macula.3 Landau et al4 reported the efficacy and accuracy of this instrument in quantitative retinal thickness measurements in healthy subjects.

We hereby present the results of retinal thickness measurements by the RTA in the macular area in a normal age matched group of patients compared with diabetic patients before and after laser treatment.

Patients and methods

PRINCIPLE OF THE RTA

The RTA operates on the principle of slit lamp biomicroscopy. A narrow (15 µm) slit of green helium neon light (543 nm), 2 mm long, is projected onto the retina at an angle of 15 degrees. The light scattered back from the retina is viewed by a RTA TV camera at an angle opposite to the angle of the incidence light. Concomitantly, a second fundus TV camera shows the fundus image for orientation of the slit. Scanning of 10 adjacent cross sections of the retina, about 200 µm apart, covering a total area of approximately 2 × 2 mm, lasts only 200 ms. Nine adjacent squares can be scanned which cover a zone of about 6 × 6 mm (20° × 20°) around the fovea. The intersection of the laser slit with the anterior
The reproducibility of the instrument was assessed by measuring the foveal thickness of 10 normal eyes. The intravisit reproducibility evaluated nine scans centred on the fovea in a single session and the intervisit reproducibility evaluated two scans of the foveal centre measured in visits 2 days apart. One hundred thickness points were measured on each scan and the coefficient of variance (SD/mean) was calculated for each of the 100 measured spots.

**PATIENT DATA**

We measured the retinal thickness in three groups of eyes of diabetic patients. Before the measurement, informed consent was obtained from all patients and healthy controls. The clinical diagnosis of these patients was determined by biomicroscopy according to early treatment diabetic retinopathy study (ETDRS) criteria and by fluorescein angiography. The first group comprised 10 eyes with cystoid macular oedema (CMO), the second group consisted of 21 eyes with clinically significant macular oedema (CSMO) without retinal cysts, and the third group included 10 eyes which were judged as having "dry" macula following previous grid pattern laser treatment due to CSMO. The results of the retinal thickness were compared with those of 46 normal eyes of age matched healthy controls. The data of the normal individuals have already been published, including the reproducibility data. The pupils were dilated with 1% tropicamide and 2.5% phenylephrine hydrochloride. An area of 6 × 6 mm, centred at the fovea, was scanned. In order to compare the retinal thickness between the various groups of eyes, the measurements at the centre of the fovea as well as four squared area of 2 × 2 mm located at 12, 3, 6, and 9 o'clock on a circle, with a radius of 500 µm centred on the fovea, were calculated and averaged.

In order to compare the retinal thickness between the four groups, analysis of variance was performed, using the multiple comparison options of Dunnet and Duncan. Analysis of variance was also done specifically for three age groups (20–34, 35–49, and 50–70 years). Probability values less or equal to 0.05 were considered statistically significant.

**Results**

The intravisit reproducibility of nine scans evaluated the centre of the fovea in a single session, obtained on the same day, was plus or minus 5.9%, corresponding to plus or minus 10.6 µm. The intervisit reproducibility of two scans evaluated the centre of the fovea, obtained on visits 2 days apart, was plus or minus 6.6%, corresponding to plus or minus 10.8 µm.

The macular thickness measurements in the various groups are displayed in Table 1. The thickness of the fovea in the CSMO eyes ranged between 200 µm and 757 µm, with an average of 427 (SD 173) µm compared with a range of 100–255 µm, with an average of 178 (44) µm in normal eyes, a 144% increase. The thickness range of the foveal centre in eyes judged as having "dry" macula after laser photo-
Table 1  RTA measurements (SD) of retinal thickness

<table>
<thead>
<tr>
<th></th>
<th>Normal eyes (46 eyes)</th>
<th>CSMO (21 eyes)</th>
<th>&quot;Dry&quot; macula (10 eyes)</th>
<th>CMO (10 eyes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foveal thickness (µm)</td>
<td>311 (51)</td>
<td>427 (175)</td>
<td>315 (71)</td>
<td>875 (287)</td>
</tr>
<tr>
<td>Macular thickness (µm)</td>
<td>566 (202)</td>
<td>566 (202)</td>
<td>414 (94)</td>
<td></td>
</tr>
</tbody>
</table>

CMO = diabetic patients with cystoid macular oedema; CSMO = diabetic patients with clinically significant macular oedema; "Dry" macula = diabetic macular oedema following laser treatment.

In the diabetic patient significant macular oedema; "Dry" macula = diabetic macular oedema following laser treatment.

coagulation was between 200 µm and 421 µm, with an average of 315 (71) µm, a 77% increase compared with the normal value, and a 26% decrease in thickness compared with the CSMO eyes. The eyes with CMO displayed the largest thickening, which ranged between 470 µm and 1230 µm, while the average was 875 (287) µm (a 390% increase compared with normal values). The average thickness at 500 µm surrounding the fovea were as follows. The CSMO eyes had an average retinal thickness of 566 (202) µm (range 221–723 µm) compared with 311 (51) µm (range 250–388 µm) in normal eyes, a 80% increase, whereas the dry macula group following laser treatment had an average thickness of 414 (94) µm (range 270–638 µm), a 27% decrease compared with the CSMO eyes, and a 33% increase compared eyes of healthy controls. These relations persisted in subgroups divided by age as well (Table 2).

Statistically significant differences were found in central thickness between the four groups (p = 0.0001). All pairwise comparisons between the groups (controls, CSMO, treated "dry" foveas, and CMO) were also statistically significant (p <0.05).

The differences in the averaged thickness of 500 µm around the foveal centre between the three groups (controls, CSMO, and treated eyes) were statistically significant, with a p value of 0.0001. The pairwise comparisons were also statistically significant (p <0.05).

In the younger age group (20–34 years), the differences in central thickness between the groups (controls and CSMO) were statistically significant, with p value of 0.0001. The pairwise comparisons were also statistically significant (p <0.05). The differences in the average thickness around the fovea between the groups (CSMO and controls) were statistically significant (p = 0.0001), and the pairwise comparisons between controls and CSMO were also significant (p <0.05).

In the second age group (35–49 years), the differences in central and average thickness around the fovea were statistically significant (p = 0.0001), the pairwise comparisons between the controls and the CSMO eyes were significant, whereas the comparisons between the controls and the “dry” treated eyes were non-significant (p = 0.05).

In the oldest age group (50–70 years), the differences in the central thickness were statistically significant (p = 0.0001), and the pairwise comparisons were significant between the CMO group and the rest of the eyes, but were not significant between the normal eyes and the CSMO and treated eyes. The differences in the average thickness around the fovea were significant (p = 0.02), and the pairwise comparisons were significant between the controls and the CSMO eyes but non-significant between the controls and the treated “dry” eyes.

Discussion

Previous investigators demonstrated the reliability of the delivery method of a green helium neon laser in a parallel beam of light and measurement of the retinal thickness in primates and in humans. These investigators measured the retinal thickness in patients with diabetic macular oedema and applied this method to quantitate macular thickness before and after focal treatment for macular oedema. The RTA is an improvement of this method and was developed to enhance the visualisation of fine structures of the retina and to measure the thickness of a scanned area of 6 × 6 mm. The green, helium neon laser illumination is ideally suited because of the narrowness of the beam, the enhanced brightness, and the monochromasy in green which reduces background scatter. These advantages allow for visualisation of fine retinal structures and measurement of the exact width of each point, as well as providing a quantitative profile of the retinal thickness of the whole scanned area.

The RTA (RetinaMap), a retinal thickness scanner provides the following advantages:

1. replacement of the contact lens by indirect optics which do not necessitate contact with the examined eye;
2. replacement of the film camera and digitalised instrumentation by an electronic camera which directly inputs the slit images acquired from the examined retina into the computer in real time;
3. a scanner is included in the optical system which allows acquisition of 10 slit images spaced evenly over a 2 mm area on the retina within 200 ms;
4. operation and analysis software for fast and easy operation of the instrument.

We investigated the correlation between subjective clinical assessment of diabetic macular

Table 2  Macular thickness (µm) measured by the RTA in age matched groups

<table>
<thead>
<tr>
<th>Age Group</th>
<th>&lt;20 years</th>
<th>20–34 years</th>
<th>35–49 years</th>
<th>50–70 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fovea</td>
<td>218 (31)</td>
<td>166 (38)</td>
<td>175 (45)</td>
<td>222 (52)</td>
</tr>
<tr>
<td>Macula</td>
<td>328 (47)</td>
<td>288 (33)</td>
<td>318 (49)</td>
<td>340 (77)</td>
</tr>
<tr>
<td>No of eyes</td>
<td>5</td>
<td>6</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>CSMO SD</td>
<td>5</td>
<td>6</td>
<td>30</td>
<td>410 (171)</td>
</tr>
<tr>
<td>No of eyes</td>
<td>5</td>
<td>6</td>
<td>352 (142)</td>
<td>542 (175)</td>
</tr>
<tr>
<td>Dry SD</td>
<td>8</td>
<td>8</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>No of eyes</td>
<td>8</td>
<td>8</td>
<td>239 (44)</td>
<td>347 (53)</td>
</tr>
</tbody>
</table>

Table 1  RTA measurements (SD) of retinal thickness

<table>
<thead>
<tr>
<th></th>
<th>Normal eyes (46 eyes)</th>
<th>CSMO (21 eyes)</th>
<th>&quot;Dry&quot; macula (10 eyes)</th>
<th>CMO (10 eyes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foveal thickness (µm)</td>
<td>311 (51)</td>
<td>427 (175)</td>
<td>315 (71)</td>
<td>875 (287)</td>
</tr>
<tr>
<td>Macular thickness (µm)</td>
<td>566 (202)</td>
<td>566 (202)</td>
<td>414 (94)</td>
<td></td>
</tr>
</tbody>
</table>

CMO = diabetic patients with cystoid macular oedema; CSMO = diabetic patients with clinically significant macular oedema; "Dry" macula = diabetic macular oedema following laser treatment.
oedema and quantitative measurements of the retinal thickness. We also measured the foveal thickness in a group of treated eyes judged clinically as having a “dry” macula for at least 4 months after treatment. Our results showed good correlation between the clinical diagnosis of macular oedema and the objective quantification of the macular thickness. The CMO retina exhibited the largest thickening, which constituted a 390% increase compared with normal values. The non-CMO oedematous macula had a 144% increase in thickness in the foveal centre compared with normal macula, and a 80% increase 500 µm around the foveal centre. The retina which were judged as being “dry” after focal laser treatment had a 26% decrease in thickness compared with the CSMO in the centre of the fovea and 500 µm around it, but still had a 77% increase compared with the normal values in the centre of the fovea and a 33% increase compared with the normal values in a circle 500 µm around the fovea. These preliminary results show that laser treatment is effective in reducing the macular thickening. They also highlight the fact that CMO constitutes a worse aspect of diabetic macular oedema compared with CSMO without cystoid changes. Its grim prognosis may be related to the degree of thickness which is more severe than in non-CMO diabetic macular oedema.

The reproducibility of the measurements was found to be plus or minus 10.6 µm of the macular thickness. These measurements were taken in a group of healthy individuals. The mean retinal thickness in the scanned area of the normal macula corresponded to the results of others.1–7

The retinal thickness analysis of diabetic macular oedema and changes occurring following focal laser treatment observed by Shahidi et al.7,8 also correspond to our results using a beam of green, helium neon laser projected on a selected narrow area of the retina.

The major advantage of the RTA is the option to scan a relatively wide area of the retinal tissue in a short acquisition time. This option is of great importance in the objective assessment of the efficacy of laser treatment in diabetic macular oedema or other therapeutic regimen, such as acetazolamide or anti-inflammatory agents, used in CMO. Moreover, the operator can easily choose a selected point of interest in the fundus and analyse the intraretinal structures in cases in which a small retinal area is affected (such as macular hole or cyst).

This method of objective measurement of the retinal thickness in various macular diseases serves as a useful and sensitive tool for the diagnosis and follow up of diabetic macular oedema, as well as for the assessment of the efficacy of laser treatment of this condition.

Retinal thickness variation in the diabetic patient measured by the retinal thickness analyser
Dov Weinberger, Ruth Axer-Siegel, David Landau and Yuval Yassur

*Br J Ophthalmol* 1998 82: 1003-1006
doi: 10.1136/bjo.82.9.1003

Updated information and services can be found at:
http://bjo.bmj.com/content/82/9/1003

These include:

**References**
This article cites 8 articles, 2 of which you can access for free at:
http://bjo.bmj.com/content/82/9/1003#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Macula (27)
- Retina (1608)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/